Abstract Search

ea0070aep628 | Pituitary and Neuroendocrinology | ECE2020

Safety and IGF-1 levels with once daily oral sst2 agonist paltusotine (CRN00808) in acromegaly patients previously treated with peptide long-acting somatostatin receptor ligands: Initial data from the open label ACROBAT Edge phase 2 study

Toth Miklos , Gordon Murray , Doknic Mirjana , Mezosi Emese , Randeva Harpal , Marmon Tonya , Fowler Kim , Luo Rosa , Monahan Michael , Madan Ajay , Ferrara-Cook Chris , Scott Struthers R. , Krasner Alan

Peptide long-acting somatostatin receptor ligands (SRLs) are a first line medical treatment for acromegaly but are not efficiently absorbed when delivered orally. Years of injections with SRLs are associated with variable dose delivery, injection site reactions, and excessive life burden. Paltusotine (CRN00808) is a nonpeptide small molecule somatostatin type 2 (sst2) receptor agonist with high oral bioavailability (70%) and a 42–50 hour terminal elimination half-life in...

0 shares

Endocrine Abstracts

Safety and IGF-1 levels with once daily oral sst2 agonist paltusotine (CRN00808) in acromegaly patients previously treated with peptide long-acting somatostatin receptor ligands: Initial data from the open label ACROBAT Edge phase 2 study

BiosciAbstracts